Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

536
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
536
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

702
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
702
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.1K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.1K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mixing apples and antibodies: when the Cochrane average obscures the evidence in Alzheimer's disease.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Long-term effects of multisession gamma transcranial alternating current stimulation in Alzheimer's disease.

Journal of Alzheimer's disease : JAD·2026
Same author

Diagnosis and management of frontotemporal dementia: a narrative review.

Neurodegenerative disease management·2026
Same author

Epilepsy and EEG abnormalities in neurodegenerative dementias: toward a system epilepsy framework.

Frontiers in aging neuroscience·2026
Same author

LAMB1-related adult-onset leukoencephalopathy presenting with cognitive decline: diagnostic workup and review of the literature.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology·2026
Same author

Multisession gamma tACS modulates extracellular vesicle dynamics.

Brain stimulation·2026

Related Experiment Video

Updated: Nov 10, 2025

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

9.0K

Experimental Disease-Modifying Agents for Frontotemporal Lobar Degeneration.

Marcello Giunta1, Eino Solje2, Fabrizio Gardoni3

  • 1Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy.

Journal of Experimental Pharmacology
|April 1, 2021
PubMed
Summary

Frontotemporal dementia (FTLD) is a complex neurodegenerative disorder linked to gene mutations and protein buildup. Current research explores small molecule therapies targeting aberrant mechanisms to slow disease progression.

Keywords:
C9orf72GRNMAPTTDP-43frontotemporal dementiafrontotemporal lobar degenerationtautherapy

More Related Videos

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.7K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.8K

Related Experiment Videos

Last Updated: Nov 10, 2025

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis
13:31

Novel Atomic Force Microscopy Based Biopanning for Isolation of Morphology Specific Reagents against TDP-43 Variants in Amyotrophic Lateral Sclerosis

Published on: February 12, 2015

9.0K
Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models
08:33

Characterizing Histone Post-translational Modification Alterations in Yeast Neurodegenerative Proteinopathy Models

Published on: March 24, 2019

7.7K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.8K

Area of Science:

  • Neuroscience
  • Genetics
  • Pharmacology

Background:

  • Frontotemporal dementia (FTLD) is a heterogeneous neurodegenerative disorder.
  • It is characterized by the accumulation of proteins like tau and TPD-43.
  • High heritability is linked to mutations in MAPT, GRN, and C9orf72 genes.

Purpose of the Study:

  • To provide insight into aberrant mechanisms causing FTLD-related proteinopathies.
  • To discuss recent therapeutic strategies for neurodegeneration in FTLD.
  • To identify potential pharmacological targets for FTLD treatment.

Main Methods:

  • Review of preclinical and clinical experimental strategies.
  • Analysis of genetic links and protein accumulation in FTLD.
  • Investigation of aberrant mechanisms driving FTLD pathophysiology.

Main Results:

  • Understanding the connection between genes and proteinopathies offers insights into FTLD pathophysiology.
  • Emerging strategies focus on small molecules over gene therapy.
  • Potential pharmacological targets have been identified.

Conclusions:

  • Aberrant mechanisms in FTLD-related proteinopathies are being elucidated.
  • New therapeutic avenues, particularly small molecule approaches, show promise.
  • These strategies aim to ameliorate neurodegeneration and slow disease progression in FTLD.